JenaValve Appoints Janet M. Fauls As Vice President Of Regulatory Affairs

IRVINE, Calif.--(BUSINESS WIRE)--JenaValve Technology, Inc., a next-generation heart-valve technology company, committed to providing state-of-the-art transcatheter aortic valve replacement (TAVR) technologies to cardiology professionals and to the broadest spectrum of patients with aortic valve disease, today announced the appointment of veteran medical device executive Janet M. Fauls as Vice President of Regulatory Affairs.

Suggested Articles

Moderna’s shares shrunk by nearly 5% before the long holiday weekend Thursday after a report out by Stat said the biotech was delaying its trial.

Keep your post-pandemic trials on track: learn how the right clinical supply chain partner can help sponsors avoid trial disruption. Read now>>

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.